ZA200401313B - Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma. - Google Patents
Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma. Download PDFInfo
- Publication number
- ZA200401313B ZA200401313B ZA200401313A ZA200401313A ZA200401313B ZA 200401313 B ZA200401313 B ZA 200401313B ZA 200401313 A ZA200401313 A ZA 200401313A ZA 200401313 A ZA200401313 A ZA 200401313A ZA 200401313 B ZA200401313 B ZA 200401313B
- Authority
- ZA
- South Africa
- Prior art keywords
- glaucoma
- estrogen
- composition
- feminizing
- feminizing estrogen
- Prior art date
Links
- 239000000262 estrogen Substances 0.000 title claims description 72
- 229940011871 estrogen Drugs 0.000 title claims description 69
- 230000001135 feminizing effect Effects 0.000 title claims description 40
- 208000010412 Glaucoma Diseases 0.000 title claims description 25
- 239000003795 chemical substances by application Substances 0.000 title claims description 10
- 230000003289 retinoprotective effect Effects 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 210000001525 retina Anatomy 0.000 claims description 11
- 210000001328 optic nerve Anatomy 0.000 claims description 10
- 206010067013 Normal tension glaucoma Diseases 0.000 claims description 9
- 201000002978 low tension glaucoma Diseases 0.000 claims description 9
- 208000028389 Nerve injury Diseases 0.000 claims description 7
- 230000008764 nerve damage Effects 0.000 claims description 7
- IBMYQCSJEBKMFF-UQCQJGFQSA-N (9r,10s,13r)-13-methyl-1,2,3,4,5,6,9,10,11,12-decahydrocyclopenta[a]phenanthren-3-ol Chemical compound C([C@@H]12)CC(O)CC1CC=C1[C@@H]2CC[C@@]2(C)C1=CC=C2 IBMYQCSJEBKMFF-UQCQJGFQSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- -1 polycyclic compound Chemical class 0.000 claims description 5
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 4
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 4
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 4
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 4
- 229960001348 estriol Drugs 0.000 claims description 4
- 229960003399 estrone Drugs 0.000 claims description 4
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000004410 intraocular pressure Effects 0.000 description 8
- 208000017442 Retinal disease Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 5
- 206010038923 Retinopathy Diseases 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000014139 Retinal vascular disease Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 241000158147 Sator Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001000594 Tanna Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101000841393 Candida albicans Probable NADPH dehydrogenase Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000492507 Sulla Species 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000033672 open angle E glaucoma 1 Diseases 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31722501P | 2001-09-05 | 2001-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401313B true ZA200401313B (en) | 2005-05-11 |
Family
ID=23232682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401313A ZA200401313B (en) | 2001-09-05 | 2004-02-18 | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1423125B1 (de) |
| JP (1) | JP2005501888A (de) |
| KR (1) | KR100894385B1 (de) |
| CN (1) | CN1551773A (de) |
| AR (1) | AR038451A1 (de) |
| AT (1) | ATE371455T1 (de) |
| AU (1) | AU2002326807B2 (de) |
| BR (1) | BR0212274A (de) |
| CA (1) | CA2458468C (de) |
| DE (1) | DE60222143T2 (de) |
| ES (1) | ES2289134T3 (de) |
| HK (1) | HK1064947A1 (de) |
| MX (1) | MXPA04002098A (de) |
| PL (1) | PL206249B1 (de) |
| TW (1) | TWI320712B (de) |
| WO (1) | WO2003020284A1 (de) |
| ZA (1) | ZA200401313B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040214806A1 (en) | 2002-09-03 | 2004-10-28 | Iok-Hou Pang | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma |
| WO2004093882A1 (ja) * | 2003-04-18 | 2004-11-04 | Advanced Medicine Research Institute | 眼に適用する疾患治療剤 |
| EP2305308A1 (de) * | 2003-04-18 | 2011-04-06 | Advanced Medicine Research Institute | Mittel zur Behandlung von Krankheiten zur Aufbringung auf das Auge |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2425849C (en) * | 1991-11-22 | 2007-02-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
| US6197833B1 (en) * | 1995-07-24 | 2001-03-06 | Apollo Biopharmaceutics, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
| US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
| AU8838601A (en) * | 2000-11-27 | 2002-06-03 | Entremed Inc | Antiangiogenic agents |
-
2002
- 2002-08-21 TW TW091118916A patent/TWI320712B/zh not_active IP Right Cessation
- 2002-08-29 AR ARP020103261A patent/AR038451A1/es unknown
- 2002-09-03 DE DE60222143T patent/DE60222143T2/de not_active Expired - Lifetime
- 2002-09-03 MX MXPA04002098A patent/MXPA04002098A/es active IP Right Grant
- 2002-09-03 CA CA2458468A patent/CA2458468C/en not_active Expired - Fee Related
- 2002-09-03 WO PCT/US2002/027969 patent/WO2003020284A1/en active IP Right Grant
- 2002-09-03 JP JP2003524591A patent/JP2005501888A/ja active Pending
- 2002-09-03 AT AT02761551T patent/ATE371455T1/de not_active IP Right Cessation
- 2002-09-03 EP EP02761551A patent/EP1423125B1/de not_active Expired - Lifetime
- 2002-09-03 KR KR1020047003273A patent/KR100894385B1/ko not_active IP Right Cessation
- 2002-09-03 BR BR0212274-0A patent/BR0212274A/pt not_active Application Discontinuation
- 2002-09-03 AU AU2002326807A patent/AU2002326807B2/en not_active Ceased
- 2002-09-03 ES ES02761551T patent/ES2289134T3/es not_active Expired - Lifetime
- 2002-09-03 CN CNA028173740A patent/CN1551773A/zh active Pending
- 2002-09-03 PL PL374243A patent/PL206249B1/pl not_active IP Right Cessation
-
2004
- 2004-02-18 ZA ZA200401313A patent/ZA200401313B/en unknown
- 2004-10-11 HK HK04107793A patent/HK1064947A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1064947A1 (en) | 2005-02-08 |
| CA2458468C (en) | 2010-08-24 |
| AU2002326807B2 (en) | 2007-08-23 |
| EP1423125A4 (de) | 2005-02-09 |
| EP1423125B1 (de) | 2007-08-29 |
| EP1423125A1 (de) | 2004-06-02 |
| PL206249B1 (pl) | 2010-07-30 |
| JP2005501888A (ja) | 2005-01-20 |
| WO2003020284A1 (en) | 2003-03-13 |
| ES2289134T3 (es) | 2008-02-01 |
| KR20040033012A (ko) | 2004-04-17 |
| DE60222143T2 (de) | 2008-06-05 |
| KR100894385B1 (ko) | 2009-04-22 |
| BR0212274A (pt) | 2004-10-19 |
| TWI320712B (en) | 2010-02-21 |
| PL374243A1 (en) | 2005-10-03 |
| AR038451A1 (es) | 2005-01-19 |
| MXPA04002098A (es) | 2004-06-07 |
| CN1551773A (zh) | 2004-12-01 |
| ATE371455T1 (de) | 2007-09-15 |
| DE60222143D1 (de) | 2007-10-11 |
| CA2458468A1 (en) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2671698A1 (en) | Treatment for dry eye using testosterone and progestagen | |
| US8865691B2 (en) | Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives | |
| US7384926B2 (en) | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma | |
| TW202135789A (zh) | 糖尿病黃斑水腫及受損之視覺敏銳度的治療 | |
| US7015210B2 (en) | Methods of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists | |
| US20060210645A1 (en) | Pharmaceutically acceptable carrier for ophthalmic compositions | |
| AU2002326807B2 (en) | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma | |
| AU2002326807A1 (en) | Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma | |
| EP1635843B1 (de) | Therapie für hormonersatz und depression enthaltend dienogest | |
| US7488723B2 (en) | Use of non-feminizing estrogens as treatment for retinal vascular diseases | |
| Rezaei et al. | Successful treatment of an extensively drug-resistant pseudomonal ulcer associated with contaminated artificial tears | |
| US20140378426A1 (en) | Methods and compositions for enhancing visual function | |
| WO2023154980A1 (en) | Treatment of anatomical and functional retinal atrophies | |
| US20070275941A1 (en) | Salt sensitivity and prevention of hypertension with drospirenone |